Drugs that contain Ceftolozane Sulfate; Tazobactam Sodium

1. Drug name - ZERBAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7129232 CUBIST PHARMS LLC Cephem compounds
May, 2028

(5 years from now)

US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(10 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(10 years from now)

US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

CN1708502A CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

CN100343260C CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

IN212088B CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

IN200500936P2 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

EP1556389B3 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 28 days from now)

EP1556389B1 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 28 days from now)

EP1556389B9 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 28 days from now)

EP1556389A1 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 28 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections Sep, 2032

(9 years from now)

US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections Sep, 2032

(9 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions Mar, 2034

(11 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions Mar, 2034

(11 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions Mar, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep, 2034

(11 years from now)

US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds Aug, 2035

(12 years from now)

Treatment: Treatment of ventilator-associated bacterial pneumonia; treatment of hospital-acquired bacterial pneumonia; Treatment of complicated urinary tract infection; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection, including pyelonephritis; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.